- Bora Pharmaceuticals has installed a high-performance Norden tube-filling line at its Mississauga, Ontario facility to support growth in dermatology product manufacturing.
- The new system increases site capacity to over 50 million units annually and offers enhanced flexibility across tube types and fill volumes.
Bora Pharmaceuticals Co., Ltd. has announced a new investment in its Mississauga, Ontario manufacturing facility with the installation of a high-speed filling line from Norden Machinery. The system is aimed at scaling up production for dermatologic formulations, as global demand in this therapeutic area continues to grow.
The new tube-filling line is the third at the site and enables the production of 7 million to 15 million additional units per year, bringing total output to more than 50 million units annually. The line supports metal, plastic, and ABL tubes, and includes laser printing, bundling, and automated shipping case packing. It is also qualified for PODA and Track and Trace serialization, aligning with the regulatory requirements of more than 20 of Bora’s global markets.
“This filling line complements our deep expertise in semi-solid formulations and strengthens our ability to help customers scale up efficiently,” said John Lawrie, VP of Operations at Bora Pharmaceuticals.
The system accommodates a wide range of fill volumes—from 2g to 150g—and is integrated with manufacturing vessels ranging from 2.5kg to 3600kg. This scalability supports both small and large batch manufacturing needs while maintaining cost efficiency. The Mississauga site is regularly inspected by global regulatory agencies and exports products across the Americas, Europe, Asia, Russia, the Middle East, and Australia.
The investment aligns with Bora’s continued focus on contract manufacturing in the dermatology space, where the global market is projected to exceed $70 billion by 2030.
